National Institute on Drug Abuse (NIDA/NIH) | Office-based Buprenorphine Treatment for OUD @NIDANIH | Uploaded September 2018 | Updated October 2024, 4 hours ago.
NIDA's Clinical Trail's Initiative (CTN) video provides an overview of Buprenorphine, a semi-synthetic opioid, used in the treatment of adults with opioid use disorder. The video highlights the opioid epidemic in the USA, the potential benefits and risks of the prescription of opioids for pain management including the risk of the development of opioid use disorder.
Of the three approved medications for MAT, the video focuses on sublingual buprenorphine. The video provides a summary of buprenorphine formulations and actions, how to start a patient on buprenorphine as well as potential side effects including the risk of relapse and overdose when it is tapered.
The video closes with instructions for obtaining a buprenorphine waiver and meet licensing requirements to prescribe buprenorphine as well as other resources for providers. For more information, check out our NIDAMED web portal: drugabuse.gov/nidamed-medical-health-professionals
This video can also be viewed at:
Comments on this video are allowed in accordance with our comment policy: newmedia.hhs.gov/standards/comment_policy.html
NIDA's Clinical Trail's Initiative (CTN) video provides an overview of Buprenorphine, a semi-synthetic opioid, used in the treatment of adults with opioid use disorder. The video highlights the opioid epidemic in the USA, the potential benefits and risks of the prescription of opioids for pain management including the risk of the development of opioid use disorder.
Of the three approved medications for MAT, the video focuses on sublingual buprenorphine. The video provides a summary of buprenorphine formulations and actions, how to start a patient on buprenorphine as well as potential side effects including the risk of relapse and overdose when it is tapered.
The video closes with instructions for obtaining a buprenorphine waiver and meet licensing requirements to prescribe buprenorphine as well as other resources for providers. For more information, check out our NIDAMED web portal: drugabuse.gov/nidamed-medical-health-professionals
This video can also be viewed at:
Comments on this video are allowed in accordance with our comment policy: newmedia.hhs.gov/standards/comment_policy.html
